Trial reportBritish journal of cancer2008
Early detection of recurrence by 18FDG-PET in the follow-up of patients with colorectal cancer.
Trial report in British journal of cancer, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 5 syntheses or guidelines pooled it, 125 citations in OpenAlex.
- Follow-up strategies following completion of primary cancer treatment in adult cancer survivors.The Cochrane database of systematic reviews · 2019Pooled it
- Follow-up strategies for patients treated for non-metastatic colorectal cancer.The Cochrane database of systematic reviews · 2019Pooled it
- Pooled it
- Follow-up strategies for patients treated for non-metastatic colorectal cancer.The Cochrane database of systematic reviews · 2016Pooled it
- The lack of evidence for PET or PET/CT surveillance of patients with treated lymphoma, colorectal cancer, and head and neck cancer: a systematic review.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2013Pooled it
- Colorectal cancer (CRC) monitoring by 6-monthly 18FDG-PET/CT: an open-label multicentre randomised trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2018Trial
- Positron emission tomography/computed tomography for optimized colon cancer staging and follow up.Scandinavian journal of gastroenterology · 2014Trial
- Diagnostic Performance of F-18 FDG PET/CT in the Detection of Recurrent Colorectal Cancer: Correlation with Biochemical Markers and Conventional Imaging Modalities.Journal of clinical medicine · 2024Article
- Intensive follow-upWorld journal of gastrointestinal oncology · 2023Article
- Surveillance strategies following curative resection and non-operative approach of rectal cancer: How and how long? Review of current recommendations.World journal of gastrointestinal surgery · 2023Review
- Utility of PET Scans in the Diagnosis and Management of Gastrointestinal Tumors.Digestive diseases and sciences · 2022Article
- The Diagnostic Performance of 18F-FDG PET/CT in Recurrent Pancreatic Cancer: A Systematic Review and Meta-analysis.Applied bionics and biomechanics · 2022Article
- [Rational staging and follow-up of colorectal cancer : Do guidelines provide further help?]Der Radiologe · 2019Review
- [Importance of FDG-PET/computed tomography in colorectal cancer].Der Radiologe · 2019Review
- The potential role of circulating tumor DNA (ctDNA) in the further investigation of colorectal cancer patients with nonspecific findings on standard investigations.International journal of cancer · 2019Article
- Early PET-CT in patients with pathological stage III colon cancer may improve their outcome: Results from a large retrospective study.Cancer medicine · 2018Article
- Peritoneal Metastases from Appendiceal Cancer.Surgical oncology clinics of North America · 2018Review
- Clinical Significance of Fluorine-18-fluorodeoxyglucose Positron Emission Tomography/computed Tomography in the Follow-up of Colorectal Cancer: Searching off Approaches Increasing Specificity for Detection of Recurrence.Radiology and oncology · 2017Article
- Surveillance after curative treatment for colorectal cancer.Nature reviews. Clinical oncology · 2017Review
- Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016.Current oncology (Toronto, Ont.) · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 11 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We assessed the potential benefits of including systematic 18fluorodeoxyglucose positron emission tomography (FDG-PET) for detecting tumour recurrence in a prospective randomised trial. Patients (N=130) who had undergone curative therapy were randomised to undergo either conventional (Con) or FDG-PET procedures during follow-up. The two groups were matched at baseline. Recurrence was confirmed histologically. 'Intention-to-treat' analysis revealed a recurrence in 46 patients (25 in the FDG-PET group, and 21 in the Con group; P=0.50), whereas per protocol analysis revealed a recurrence in 44 out of 125 patients (23 and 21, respectively; P=0.60). In another three cases, PET revealed unexpected tumours (one gastric GIST, two primary pulmonary cancers). Three false-positive cases of FDG-PET led to no beneficial procedures (two laparoscopies and one liver MRI that were normal). We failed to identify peritoneal carcinomatosis in two of the patients undergoing FDG-PET. The overall time in detecting a recurrence from the baseline was not significantly different in the two groups. However, recurrences were detected after a shorter time (12.1 vs 15.4 months; P=0.01) in the PET group, in which recurrences were also more frequently (10 vs two patients) cured by surgery (R0). Regular FDG-PET monitoring in the follow up of colorectal cancer patients may permit the earlier detection of recurrence, and influence therapy strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.